{"id":"dfd-03","safety":{"commonSideEffects":[{"rate":null,"effect":"Testosterone suppression"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5959317","moleculeType":null,"molecularWeight":"379.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DFD-03 selectively activates androgen receptors in muscle and bone tissue, promoting anabolism and muscle growth with reduced activity in prostate and other androgenic tissues. This selective tissue distribution aims to provide the therapeutic benefits of androgens while reducing unwanted androgenic and estrogenic adverse effects associated with traditional hormone therapies.","oneSentence":"DFD-03 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:47.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting and cachexia"},{"name":"Sarcopenia in aging populations"}]},"trialDetails":[{"nctId":"NCT03292640","phase":"PHASE3","title":"A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-07-06","conditions":"Acne Vulgaris","enrollment":547},{"nctId":"NCT03290027","phase":"PHASE3","title":"A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-07-31","conditions":"Acne Vulgaris","enrollment":550},{"nctId":"NCT03599193","phase":"PHASE2","title":"A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-10-04","conditions":"Acne Vulgaris","enrollment":58},{"nctId":"NCT03341910","phase":"PHASE2","title":"A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-08-21","conditions":"Acne Vulgaris","enrollment":155}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazarotene 0.1% Lotion"],"phase":"phase_3","status":"active","brandName":"DFD-03","genericName":"DFD-03","companyName":"Dr. Reddy's Laboratories Limited","companyId":"dr-reddy-s-laboratories-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DFD-03 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting and cachexia, Sarcopenia in aging populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}